ValiRx
plc
("ValiRx" or the "Company")
Investor Evening - Tuesday 24
September 2024
London, UK - ValiRx Plc is pleased
to welcome current shareholders and interested investors to a
ValiRx Plc Investor Evening organised by Shard Capital Partners LLP
on Tuesday, 24 September 2024.
At the event, a presentation will be
delivered by Dr Mark Eccleston, Chief Executive of the Company,
followed by a Q&A session. Drinks will be provided.
The event will take place
at 25 Eccleston Place London SW1W
9NF, London and will start at 5.30pm
(UK).
To gain admission, please RSVP by
completing the attendance form via the following link:
https://corporate-update-from-fusion-antibodies-plc-and-valirx-plc-tick.eventbrite.co.uk
The Directors of the Company take
responsibility for this announcement.
*** ENDS
***
For more information, please
contact:
|
ValiRx plc
Dr Mark Eccleston, CEO
|
Tel: +44 (0) 115 784 0026
www.valirx.com
info@valirx.com
|
|
V
Formation (Public Relations)
Lucy Wharton - Senior PR
Executive
Sue Carr - Director
|
+44
(0) 115 787 0206
www.vformation.biz
lucy@vformation.biz
sue@vformation.biz
|
|
Cairn Financial Advisers LLP (Nominated
Adviser)
Liam Murray/Jo Turner/Ludovico
Lazzaretti
|
Tel: +44 (0) 20 7213 0880
|
|
Shard Capital Partners LLP (Sole Broker)
Damon Heath
|
Tel: +44 (0) 20 7186 9000
|
Notes for Editors
About ValiRx
ValiRx is a life science company
focused on early-stage cancer therapeutics and women's health,
accelerating the translation of innovative science into impactful
medicines to improve patient lives.
ValiRx provides the scientific,
financial, and commercial framework for enabling rapid translation
of innovative science into clinical development.
Using its extensive and proven
experience in research and drug development, the team at ValiRx
selects and incubates promising novel drug candidates and guides
them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines
across scientific, technical, and commercial domains, with the aim
of achieving a more streamlined, less costly, drug development
process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for
science to advance.
Lead candidates from ValiRx's
portfolio are outlicensed or partnered with investors through
ValiRx subsidiary companies for further clinical development and
commercialisation.
ValiRx listed on the AIM Market of
the London Stock Exchange in October 2006 and trades under the
ticker symbol: VAL.
For further information,
visit: www.valirx.com
Cautionary statement
Certain statements made in this
announcement are forward-looking statements. Such statements are
based on current expectations and assumptions and are subject to a
number of risks and uncertainties that could cause actual events or
results to differ materially from any expected future events or
results expressed or implied in these forward-looking statements.
Persons receiving this announcement should not place undue reliance
on forward-looking statements. Unless otherwise required by
applicable law, regulation or accounting standard, the Company does
not undertake to update or revise any forward-looking statements,
whether as a result of new information, future developments or
otherwise.